Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Plasmodium vivax ookinete surface protein 25 (Pvs25)
- Target
- Pvs25
- Molecular classification
- Other (surface protein), Transmission-blocking vaccine antigen, Ookinete surface protein
01
Overview
Plasmodium vivax ookinete surface protein 25 (Pvs25) is a cysteine-rich, surface-exposed protein expressed on the zygote and ookinete stages of P. vivax in the mosquito midgut. Structurally, Pvs25 contains four EGF-like domains stabilized by 11 disulfide bonds. It plays a key role in the parasite's development within mosquitoes and is absent from human blood stages. Pvs25 is a leading candidate for malaria transmission-blocking vaccines: antibodies raised against Pvs25 can inhibit parasite development in the mosquito, thus preventing onward transmission to humans. Pvs25 is highly conserved, but recombinant expression is technically challenging due to its complex disulfide-bonded structure. Previous protein subunit vaccines have shown potent transmission-blocking immunity in animal models, but immunogenicity in humans was suboptimal, driving interest in novel platforms, like mRNA vaccines, to improve efficacy[1][3][4][5][7][8].
- Other names
- P25Ookinete surface protein Pvs25
02
Mechanism of action
Transmission-blocking by eliciting antibodies that prevent parasite development in mosquitoes
03
Biological functions
Parasite surface structureTransmission of malaria (mosquito stage)Immune response induction (as a vaccine antigen)
04
Disease associations
Infection (malaria transmission)Other (vaccine target)
05
Safety considerations
Limited natural immunogenicity in humansRequires adjuvant or novel presentation (e.g., mRNA platforms) for potent immune responsePotential vaccine production challenges due to complex disulfide bonds and protein folding requirements
06
Biomarkers
Antibodies to Pvs25 (as a marker of transmission-blocking immunity)
Beyond the preview
Go deeper on Plasmodium vivax ookinete surface protein 25 (Pvs25).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Plasmodium vivax ookinete surface protein 25 (Pvs25).